

UK NEOQAS

Leucocyte Immunophenotyping

Title:	Molecular Trial Schedule
Index:	Administration 444
Authors:	Caley Wilks, Debbie Travis, and Stuart Scott
Version:	5.0
Authorised By:	Debbie Travis
Authorisation Date:	07-Nov-2019
Review Date:	07-Nov-2020
Location Of Copy:	unknown

Uncontrolled Copy

TRIAL SCHEDULE 2020-2021

	BCR-ABL1 and AML Translocation Identification (Accredited)	BCR-ABL1 Major Quantification (Accredited)	Post-Stem Cell Transplant Chimerism Monitoring (Accredited)	IgH/TCR Clonality Status (Accredited)	JAK2 p.Val617Phe (V617F) Mutation Status (Accredited)	FLT3 Mutation Status (Accredited)	NPM1 Mutation Status (Accredited)	BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia (Accredited)	KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease (Accredited)	Paediatric Acute Leukaemia Translocations (Accredited)	BCR-ABL1 Minor Quantification (Pilot - Not Accredited)	BCR-ABL1 Kinase Domain Mutation Status (Pilot - Not Accredited)	Acute Myeloid Leukaemia and Myelodysplastic Syndrome Gene Panels (Pilot - Not Accredited)	Chronic Lymphocytic Leukaemia Gene Panels (Pilot - Not Accredited)	Myeloproliferative Neoplasms Gene Panels (Pilot - Not Accredited)	Lymphoplasmacytic Lymphoma / Waldenström Macroglobulinaemia (Pilot - Not Accredited)
Planned trial issues per financial year	3	3	5	3	3	3	3	3	3	3	2	2	2	1	1	1
APRIL 2020	X			X				X								
MAY 2020		X	X						X							
JUNE 2020					X					X				X		
JULY 2020			X			X	X	X								
AUGUST 2020	X			X								X	X			
SEPTEMBER 2020		X							X		X				X	
OCTOBER 2020			X		X					X						
NOVEMBER 2020						X	X									X
DECEMBER 2020	X			X				X								
JANUARY 2021		X	X						X		X					
FEBRUARY 2021					X					X		X	X			
MARCH 2021			X			X	X									

Please note that this is a guide only. UK NEQAS for Leucocyte Immunophenotyping reserves the right to cancel or vary the number of shipments. Please note that your participation entitles you to the service and not the number of shipments.